香 港 聯 合 交 易 所 有 限 公 司 與 證 券 及 期 貨 事 務 監 察 委 員 會 對 本 申 請 版 本 的 內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 意 見，並 明 確 表 示 概 不 就 因 本 申 請 版 本 全 部 或 任 何 部 分 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 的 任 何 損失承擔任何責任。 Hangzhou Sciwind Biosciences Co., Ltd.* 杭州先為達生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 的申請版本 警 告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）與證券及期貨事務監察委員會（「證監會」）的要求而刊發， 僅用作提供資訊予香港公眾人士。 本申請版本為草擬本，其內所載資料並不完整，亦可能會作出重大變動。 閣下閱覽本文件，即代表 閣下知悉、 接納並向本公司、其保薦人、整體協調人、顧問或包銷團成員表示同意： 本公司招股章程根據香港法例第32章《公 司（清 盤 及 雜 項 條 文）條 例》呈 交 香 港 公 司 註 冊 處 處 長 登 記 前，本 公 ...

Core Viewpoint - The article discusses the potential of Semaglutide, a GLP-1 receptor agonist, in treating osteoarthritis beyond weight loss, suggesting it may directly influence cartilage metabolism and structural progression of the disease [6][8][11]. Group 1: Current Understanding of Osteoarthritis - Osteoarthritis has long been viewed as a degenerative disease that is difficult to reverse, with treatment primarily focused on symptom control rather than structural repair [5]. - There are over 500 million osteoarthritis patients globally, yet there is still a lack of recognized disease-modifying therapies [5]. Group 2: New Research Insights - Recent studies indicate that Semaglutide shows significant cartilage protection in osteoarthritis models, with reductions in cartilage degeneration, bone spur formation, and pain sensitivity [6][8]. - The research aims to differentiate the effects of Semaglutide from mere weight loss benefits, proposing that it may reshape cartilage cell energy metabolism [6][8]. Group 3: Implications for Treatment - The findings suggest a shift in understanding osteoarthritis treatment, indicating that metabolic interventions could be integral to joint protection rather than peripheral strategies [11]. - Semaglutide's role may evolve from being solely a metabolic disease drug to a potential interdisciplinary treatment tool connecting obesity, inflammation, and joint degeneration [11][12]. Group 4: Future Research Directions - The current evidence is primarily based on animal models and early-stage human studies, necessitating larger clinical trials to confirm efficacy in delaying joint structural deterioration and achieving cartilage repair [13]. - Despite promising signals, Semaglutide is not yet approved for osteoarthritis treatment, and further research is needed to explore its full potential in this area [13].

Core Viewpoint - Thailand has tightened regulations on GLP-1 weight loss injections, requiring a doctor's prescription for purchase, thus returning these medications to a medical management framework [4][5]. Regulatory Changes - The Thai FDA has classified injectable GLP-1 drugs as controlled substances, necessitating prescriptions from licensed pharmacies for purchase [4]. - The new regulations aim to address the misuse of GLP-1 drugs, which have been marketed as quick weight loss solutions on social media [5]. Market Impact - The new rules will primarily affect the weight loss consumer segment, making it more difficult for individuals to obtain these drugs through informal channels [5]. - The shift will benefit legitimate healthcare providers and pharmacies, as the role of regulated medical systems will increase [5]. Clinical Access - Patients with clinical needs, such as those with type 2 diabetes or obesity, can still access GLP-1 medications under medical supervision [6]. - The regulations signal a clear message that weight loss drugs should remain within the medical domain and not be commercialized as easy solutions for the general public [6].

Core Viewpoint - The article discusses the significant upgrade of oral semaglutide, which is redefining the competitive landscape in the GLP-1 drug market by enhancing the formulation and delivery system, thus raising the bar for future competitors [2][3][5][7]. Group 1: Product Upgrade - The new formulation of oral semaglutide features optimized dosages of 1.5 mg, 4 mg, and 9 mg, compared to the original 3 mg, 7 mg, and 14 mg, indicating improved absorption efficiency at lower doses [2][3]. - The upgrade is not merely a reduction in dosage but reflects advancements in the formulation design and delivery efficiency, achieving equivalent exposure with lower doses [2][3]. Group 2: Delivery System Challenges - Oral peptide drugs face significant challenges, including degradation in the gastrointestinal environment, destruction by digestive enzymes, and poor permeability through epithelial barriers [3]. - The delivery strategy centered around SNAC has been crucial in enhancing the absorption conditions in the stomach and facilitating effective trans-mucosal penetration, significantly improving the oral bioavailability of semaglutide [3]. Group 3: Competitive Landscape - The complexity of replicating the oral semaglutide delivery system makes it more challenging for generic manufacturers compared to injectable forms, as the core logic of the delivery platform remains difficult to duplicate [5]. - The proactive upgrade of the formulation by the original manufacturer serves as a defensive strategy, enhancing product competitiveness and raising the entry barriers for potential competitors [5][7]. Group 4: Industry Implications - The upgrade of oral semaglutide signals a shift in the peptide drug industry, where the competitive edge increasingly relies on formulation platforms and delivery capabilities rather than just the active molecule itself [7]. - For generic drug companies, the rules of engagement have changed, making it more complex to enter the market, as the focus will now be on achieving convenience, stability, and efficiency in drug delivery [7].

Core Viewpoint - Eli Lilly plans to invest a total of $3 billion over the next decade to expand its supply chain capacity in China, focusing on local production and supply of oral solid formulations, particularly for the GLP-1 receptor agonist Orforglipron [2][4]. Group 1: Investment Details - The investment marks Eli Lilly's second major commitment in China within two years and is part of the largest global production expansion plan in the company's history [1]. - The investment strategy combines internal expansion at the Suzhou facility with external collaborations, enhancing both production capacity and supply chain procurement [3][6]. - The total expected investment in China will rise to nearly $6 billion, with over 20 new drugs and indications anticipated in the next three years and more than 30 over the next decade [7]. Group 2: Product Focus - Orforglipron is the world's first registered oral small molecule GLP-1 receptor agonist, with expectations for it to be among the first to market globally [5]. - The Suzhou facility, established in 1996, is Eli Lilly's only owned production base in China, responsible for producing insulin and tablets for both domestic and international markets [4]. Group 3: Strategic Partnerships - Eli Lilly has formed a strategic partnership with WuXi AppTec, planning to invest $200 million to support its technological capabilities [2][6]. - The collaboration aims to enhance local manufacturing and supply of key innovations, with projected peak annual production capacity reaching several billion tablets [6].

Core Viewpoint - The value of Semaglutide, a GLP-1 receptor agonist, has expanded beyond glucose control and weight loss to include cardiovascular outcomes, renal protection, metabolic remodeling, and long-term chronic disease management, particularly in the Chinese patient population [2][3]. Group 1: Chinese Chronic Disease Management - The burden of cardiovascular disease in China is significant, with stroke accounting for nearly 50% of cardiovascular deaths, a rate higher than in Western countries and East Asian neighbors [3]. - Chinese type 2 diabetes patients typically have a lower average BMI than Western populations but experience earlier and more pronounced beta-cell dysfunction [5]. Group 2: Cardiovascular Benefits - Semaglutide has demonstrated a 26% reduction in major adverse cardiovascular events (MACE) in the SUSTAIN 6 study, with an even greater reduction of 27% in Asian populations [6][8]. - The drug significantly reduces non-fatal stroke risk by 39%, addressing a critical clinical concern in China where stroke is a leading cause of cardiovascular mortality [7]. Group 3: Metabolic Management - In the SUSTAIN China study, Semaglutide treatment led to an average HbA1c reduction of 1.8%, with an 86.1% rate of patients achieving HbA1c below 7.0% [8][11]. - The drug also resulted in an average weight loss of 4.0 kg and a reduction in systolic blood pressure by 7.1 mmHg, indicating its comprehensive impact on metabolic health [11]. Group 4: Weight Loss Efficacy - In the STEP 7 study, Semaglutide 2.4 mg resulted in an average weight loss of 11.8% and a waist circumference reduction of 10.2 cm over 44 weeks, which is particularly significant for overweight and obese patients in China [12]. - The rising obesity rates in China, projected to reach 70.5% by 2030, highlight the importance of effective long-term management solutions like Semaglutide [12]. Group 5: Early Cardiovascular Benefits - The SELECT study showed that Semaglutide 2.4 mg reduced MACE risk by 20% in overweight or obese patients with cardiovascular disease, with a notable 41% reduction in MACE risk observed within just six months of treatment [13][14]. - These findings suggest that the cardiovascular benefits of Semaglutide may manifest even before significant weight loss occurs, indicating its potential for early intervention [13]. Group 6: Safety and Long-term Use - Semaglutide has a well-established safety profile, with the most common side effects being mild gastrointestinal issues that are manageable through established clinical practices [15]. - The drug's long-term usability is enhanced by physicians' familiarity with managing its side effects, which is crucial for chronic disease management [15]. Group 7: Evolving Standards in Chronic Disease Management - Semaglutide is evolving from a traditional diabetes and weight loss medication to a comprehensive tool for managing chronic diseases in China, supported by robust local evidence and clinical outcomes [16][18]. - The focus of chronic disease management is shifting towards early risk reduction and comprehensive metabolic control rather than solely on rapid glucose reduction or weight loss [18].

Core Insights - Eli Lilly's Orforglipron has shown superior results in the ACHIEVE-3 clinical trial compared to oral semaglutide, demonstrating significant improvements in A1C reduction and weight loss [4][7][8] - Orforglipron is expected to receive approval in Q2 2026, with advantages over oral Wegovy in terms of production scalability, cost-effectiveness, and no fasting requirements for administration [4][8] - The introduction of Orforglipron is anticipated to drive revenue growth for domestic CDMO companies due to its complex synthesis process and high raw material costs, similar to the rapid uptake seen with Paxlovid [4][9] - Investment recommendations focus on companies with strong capabilities in small molecule CDMO production, including WuXi AppTec, Kelun Pharmaceutical, and others [4] Industry Performance Review - The pharmaceutical and biotechnology sector's TTM-PE ratio stands at 46.32, representing a 90% increase from its historical low of 24.38, with a premium of 226% over the CSI 300 index [11] - The sector has experienced a decline of 2.78% in the past week, ranking 14th among 27 sub-industries [17] - Notable individual stock performances include Xinhongcheng with a 15.24% increase and *ST Guohua with a 22.61% decrease [21] Industry Dynamics - Recent approvals include new indications for various drugs, such as the non-covalent BTK inhibitor from Innovent and Eli Lilly, and the CDK2/4/6 inhibitor from Xuan Bamboo Biotech [23][24] - The approval of Orforglipron is expected to enhance the competitive landscape in the GLP-1 receptor agonist market, particularly against Novo Nordisk's oral Wegovy [8][10]

Core Viewpoint - The approval of Tirzepatide for the treatment of Obstructive Sleep Apnea (OSA) marks a significant milestone, expanding the application of GLP-1 receptor agonists beyond weight loss and diabetes management to metabolic diseases and sleep medicine [4][8]. Group 1: GLP-1 Drugs and OSA - GLP-1 receptor agonists like Semaglutide and Tirzepatide have gained attention for their significant weight loss and glycemic control effects, with recent approvals indicating a shift in treatment paradigms for OSA [4][6]. - The approval of Tirzepatide for OSA is the first of its kind, based on the SURMOUNT-OSA study, which demonstrated a significant reduction in the Apnea-Hypopnea Index (AHI) in obese patients, with some transitioning from severe to mild OSA or complete resolution [8][9]. - Patients using Tirzepatide experienced an 18% to 20% reduction in body weight, alongside a notable decrease in high-sensitivity C-reactive protein, indicating reduced systemic inflammation and improved sleep quality [9][11]. Group 2: Mechanisms and Implications - GLP-1 drugs may influence not only weight loss but also metabolic, inflammatory, and neuroregulatory mechanisms, potentially improving sleep quality beyond just weight reduction [6][11]. - Chronic inflammation associated with obesity and OSA can exacerbate airway issues; thus, reducing inflammation through GLP-1 drugs may enhance overall sleep quality [11]. - The potential for GLP-1 drugs to affect REM sleep, emotional regulation, and neuroprotection suggests a broader impact on sleep health and related disorders, including anxiety and depression [11][12]. Group 3: Limitations and Future Directions - Not all OSA patients are suitable candidates for GLP-1 drugs, as approximately 20% of adults with OSA are not obese, and other anatomical factors may contribute to airway obstruction [12]. - The integration of GLP-1 drugs into a comprehensive treatment framework is essential, emphasizing the importance of lifestyle modifications alongside pharmacotherapy to maintain long-term health and prevent weight regain [12]. - Researchers believe that the application of Tirzepatide in OSA is just the beginning, with the potential to redefine treatment approaches for sleep apnea and related conditions [12].

Core Viewpoint - The approval of IcoSema, a combination of long-acting insulin and GLP-1 receptor agonist, addresses the dual challenges of managing HbA1c levels while minimizing weight gain and treatment complexity in type 2 diabetes management in China [5][8][10] Summary by Sections Product Overview - IcoSema combines two active ingredients: icodec, a long-acting insulin with a half-life of approximately 200 hours, and semaglutide, a GLP-1 receptor agonist with a half-life of about 165 hours, allowing for weekly injections [5] - This combination aims to simplify treatment pathways for patients transitioning from oral medications to insulin therapy, addressing concerns about injection complexity and weight gain [8] Clinical Evidence - The efficacy of IcoSema is supported by three Phase III studies (COMBINE 1, 2, and 3), demonstrating superior HbA1c reduction compared to traditional insulin and semaglutide alone [9] - COMBINE 1 showed a greater reduction in HbA1c with IcoSema while highlighting a divergence in weight changes, indicating metabolic benefits of the combination [9] - COMBINE 2 indicated that while IcoSema is effective for HbA1c improvement, its weight management effects are less pronounced than those of semaglutide alone, suggesting it is tailored for patients needing stronger glycemic control [9] - COMBINE 3 reinforced IcoSema's advantages in complex insulin regimens, showing effective glycemic control with reduced weight burden [9] Market Implications - The approval of IcoSema represents a strategic positioning for Novo Nordisk in the competitive GLP-1 market in China, shifting focus from single-agent GLP-1 competition to comprehensive glycemic control solutions [10] - The market penetration of IcoSema will depend on pricing, acceptance among healthcare providers, and its positioning relative to existing treatments like semaglutide and long-acting insulin [10] - IcoSema is expected to first be adopted in specialized endocrinology and chronic disease management settings before expanding to broader outpatient follow-up scenarios [10]

Core Viewpoint - Obesity is a chronic and progressive disease that poses significant public health challenges globally, with a sharp increase in prevalence since 1975, affecting over 2.5 billion adults worldwide, including 34.8% of Chinese adults classified as overweight and 14.1% as obese [2][3]. Group 1: Obesity and Its Implications - The clinical consequences of obesity are severe, being a recognized risk factor for multiple complications such as insulin resistance, type 2 diabetes, dyslipidemia, hypertension, cardiovascular diseases, and metabolic dysfunction-related fatty liver disease [2]. - There is an urgent need for effective and sustainable interventions to control obesity and its related complications [2]. Group 2: Treatment Advances - The foundation of weight management remains comprehensive lifestyle interventions, including dietary adjustments, increased physical activity, and behavioral therapy, although achieving and maintaining clinically significant weight loss through these methods can be challenging [5]. - Recent advancements in pharmacological treatments for obesity, particularly with the development of GLP-1 receptor agonists, have shown significant weight loss effects and various beneficial multi-faceted effects, including improved blood glucose control, reduced blood pressure, and improved lipid profiles [5]. Group 3: Bofanglutide Clinical Trials - Bofanglutide, a long-acting GLP-1 receptor agonist developed by Ganli Pharmaceutical, has a pharmacokinetic profile that allows for bi-weekly dosing, showing promise as a potential treatment option for weight management and type 2 diabetes [6]. - In a phase 2b clinical trial involving overweight or obese adults in China, Bofanglutide demonstrated good overall tolerability and significant weight loss, with participants losing between 9.75% to 16.69% of their body weight over 30 weeks compared to a mere 1.15% in the placebo group [8][10]. - The trial included 340 participants, with a majority completing the study, and highlighted the need for less frequent dosing to improve treatment adherence and sustainability [8][10]. Group 4: Safety and Efficacy - The study indicated that Bofanglutide treatment resulted in a dose-dependent reduction in weight and significant improvements in cardiovascular metabolic risk factors, with manageable safety profiles even at higher doses [10]. - The findings support the further development of Bofanglutide as a bi-weekly administered formulation for effective weight management [10].